Optimizing Outcomes in Patients with FSGS: A Case-Based Approach in the New Era of Targeted Therapy
Jörg Latus, MD
Sayna Norouzi, MD
Swing for the Fences – LDL-C as the Power Hitter
J.A. Randy Englert, MD, FACC
Matthew Malachowski, Pharm. D., MHA
Small Ball Wins Games – Combination Therapy for Goal Attainment
Crossing Home Plate – Building a Winning Team Culture
Turning the Double Play – Comprehensive Secondary Prevention
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Safety in oHCM Therapy: How and When to Transition Treatment?
Anjali Owens, MD
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Ahmad Masri, MD, MS
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Michael Nassif, MD, MSc
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Cracking the Code of Obstruction: Unmet Needs in oHCM
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Is CKD-aP Hiding in Your Dialysis Center?
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD